Abstract
Schiff bases of isatin 1-20 were synthesized and tested for their antiglycation potential. Compound 6 showed 77% inhibition with an IC50= 177.2 ± 0.4 μM, which is an excellent antiglycation activity, if compared with standard aminoguanidine having 85.69% inhibition with an IC50 value 268.7 ± 12.4 μM. Compound 3 showed 71.3% inhibition with an IC = 675 ± 0.12 μ/M, which is moderately active antiglycation agent. Although compounds 1, 2, 5, 7-15, and 17- 19 demonstrated over 50% inhibition in preliminary screening, but found inactive when further evaluated for their IC values. However, compounds 4, 16, 20, and parent isatin showed less than 50% inhibition and considered to be completely inactive. The structures of all the synthesized compounds were determined by spectroscopic analysis, including UV, IR, mass and 1H-NMR spectrometry. All compounds gave satisfactory elemental analysis.
Keywords: Synthesis, Isatin, Schiff bases, Antiglycation, Lead molecules
Letters in Drug Design & Discovery
Title: Schiff Bases of Istain: Antiglycation Activity
Volume: 6 Issue: 5
Author(s): Khalid Mohammed Khan, Uzma Rasool Mughal, Nida Ambreen, Ambreen Khan, Shahnaz Perveen and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Synthesis, Isatin, Schiff bases, Antiglycation, Lead molecules
Abstract: Schiff bases of isatin 1-20 were synthesized and tested for their antiglycation potential. Compound 6 showed 77% inhibition with an IC50= 177.2 ± 0.4 μM, which is an excellent antiglycation activity, if compared with standard aminoguanidine having 85.69% inhibition with an IC50 value 268.7 ± 12.4 μM. Compound 3 showed 71.3% inhibition with an IC = 675 ± 0.12 μ/M, which is moderately active antiglycation agent. Although compounds 1, 2, 5, 7-15, and 17- 19 demonstrated over 50% inhibition in preliminary screening, but found inactive when further evaluated for their IC values. However, compounds 4, 16, 20, and parent isatin showed less than 50% inhibition and considered to be completely inactive. The structures of all the synthesized compounds were determined by spectroscopic analysis, including UV, IR, mass and 1H-NMR spectrometry. All compounds gave satisfactory elemental analysis.
Export Options
About this article
Cite this article as:
Khan Mohammed Khalid, Mughal Rasool Uzma, Ambreen Nida, Khan Ambreen, Perveen Shahnaz and Choudhary Iqbal Muhammad, Schiff Bases of Istain: Antiglycation Activity, Letters in Drug Design & Discovery 2009; 6 (5) . https://dx.doi.org/10.2174/1570180810906050358
DOI https://dx.doi.org/10.2174/1570180810906050358 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evolving Therapeutic Targets in Ischemic Stroke: A Concise Review
Current Drug Targets Understanding the Role of Aldose Reductase in Ocular Inflammation
Current Molecular Medicine Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction
Current Drug Targets Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Protein Misfolding in Disease and Small Molecule Therapies
Current Topics in Medicinal Chemistry Role of Neurotrophins in Spinal Plasticity and Locomotion
Current Pharmaceutical Design Targeting Epigenetics in Nervous System Disease
CNS & Neurological Disorders - Drug Targets Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Combating Protein Misfolding and Aggregation by Intracellular Antibodies
Current Molecular Medicine Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Relationship Between Body Mass Index and Reproduction
Current Women`s Health Reviews Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cell-Based Therapy for the Treatment of Type 1 Diabetes Mellitus
Current Stem Cell Research & Therapy Life and Death of Nerve Cells: Therapeutic Cytokine Signaling Pathways
Current Signal Transduction Therapy Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini- Review
CNS & Neurological Disorders - Drug Targets